BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

2021/11/19 by Maria Reig, María Reig, Alejandro Forner +17 · 20 citations
Medicine · #Gastric Cancer Management and Outcomes #Hepatocellular Carcinoma Treatment and Prognosis #Lung Cancer Research Studies

paper · pdf · doi:10.1016/j.jhep.2021.11.018

openalex publication_date 2021/11/19 · crossref created 2021/11/19 · crossref issued 2022/03/01 · crossref published 2022/03/01 · crossref published-print 2022/03/01 · openalex created_date 2025/10/10 · crossref deposited 2026/04/30 · crossref indexed 2026/07/30 · openalex updated_date 2026/07/31

Citations

• Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
• Comparative Short-term Benefits of Laparoscopic Liver Resection
• Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference
• Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Cited by

• Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy
• Precision surgery for hepatocellular carcinoma
• Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma
• The evolving concept of conversion surgery for upfront unresectable upper gastrointestinal and hepato-pancreato-biliary cancers: comprehensive review
• Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab–bevacizumab
• Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV)
• Hepatocellular carcinoma management in older adults and its relation with frailty
• The current landscape of therapies for hepatocellular carcinoma
• Comparison of dosimetry models to predict outcome for radioembolization in patients with intermediate to advanced hepatocellular carcinoma
• Comparative Radiologic Response Assessment after Transarterial Chemoembolization, Percutaneous Ablation, and Multimodal Treatment: Radiologic-Pathologic Correlation in 81 Tumors
• Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study
• Predictors of early and late hepatocellular carcinoma recurrence
• Imaging-based diagnosis of hepatocellular carcinoma: Liver Imaging Reporting and Data System and beyond
• Active Electromagnetic Interference Suppression for MRI and Proton Resonance Frequency Shift Thermometry During MRI ‐Guided Microwave Ablation
• Prognostic Divergence in Human Immunodeficiency Virus/Hepatitis B Virus Versus Hepatitis B Virus–Associated Hepatocellular Carcinoma After Resection: Intrahepatic Pre-S Deletions Mutants and T-Cell Depletion Under Viral Suppression
• Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
• Traditional herbal medicine as an adjuvant therapy for preventing the recurrence of hepatocellular carcinoma after radical resection: Development and validation of a machine learning prediction model
• Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study
• Liver transplantation as a treatment for cancer: comprehensive review
• Prediction of treatment response and outcome of transarterial chemoembolization in patients with hepatocellular carcinoma using artificial intelligence: A systematic review of efficacy